Motzer RJ, Penkov K, Haanen JBAG, et al. JAVELIN Renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC). ESMO 2018, abstract LBA6_PR.
Nivolumab plus ipilimumab versus sunitinib bij gevorderd RCC: extended follow-up CheckMate 214
okt 2019 | Uro-oncologie